Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 4/2001

01-04-2001 | Review Article

Symptom and Health-Related Quality-of-Life Measures for Use in Selected Gastrointestinal Disease Studies

A Review and Synthesis of the Literature

Authors: Anne M. Rentz, Carmelina Battista, Elyse Trudeau, Robert Jones, Patricia Robinson, Sheldon Sloan, Sonika Mathur, Lori Frank, Dennis A. Revicki

Published in: PharmacoEconomics | Issue 4/2001

Login to get access

Abstract

Patient-rated symptom and health-related quality-of-life (HR-QOL) outcomes are important end-points for clinical trials of medical treatments for gastrointestinal (GI) disorders. Based on this review, patient outcomes research is focused on gastroesophageal reflux disease and dyspepsia, with a growing interest in irritable bowel syndrome but little research in gastroparesis. State-of-the-art for patient-rated symptom scales is rudimentary with an abundance of scales and little attention to systematic instrument development or comprehensive psychometric evaluation. Generally, disease-specific HR-QOL measures have been more systematically developed and evaluated psychometrically, but few have been incorporated into clinical trials. More comprehensive outcome assessments are needed to determine the effectiveness of new medical treatments for functional GI disorders. Future clinical trials of GI disorders should combine clinician assessments of outcomes and symptoms with patient-rated symptom and HR-QOL end-points.
Literature
1.
Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976; 21: 953–6PubMedCrossRef
2.
Farup C, Kleinman L, Sloan S, et al. The association of nocturnal gastroesophageal reflux disease symptoms and health-related quality of life. Bethesda (MD): MEDTAP International, 1999
3.
Frank L, Kleinman L, Ganoczy D, et al. Upper gastrointestinal symptoms in North America: prevalence and relationship to healthcare utilization and quality of life. Dig Dis Sci 2000; 45: 809–18PubMedCrossRef
4.
Talley NJ, Zinsmeister AR, Schleck CD, et al. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992; 102: 1259–68PubMed
5.
Agreus L, Svardsudd K, Nyren O, et al. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 1995; 109: 671–80PubMedCrossRef
6.
Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review of practice guideline development. Gastroenterology 1997; 112: 2120–37PubMedCrossRef
7.
Horowitz M, Wishart JM, Jones KL, et al. Gastric emptying in diabetes: an overview. Diabet Med 1996; 13: 9 Suppl. 5: S16-S22
8.
Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labelling and promotion. Value Health 1999; 2: 113–27APubMedCrossRef
9.
10.
Revicki DA, Ehreth JL. Health-related quality of life assessment and planning for the pharmaceutical industry. Clin Ther 1997; 19: 1101–15PubMedCrossRef
11.
Patrick D, Erickson P. Health status and health policy: allocating resources to health care. New York (NY): Oxford University Press, 1993
12.
Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia (PA): Lippincott-Raven, 1996
13.
McDowell I, Newell C. Measuring health: a guide to rating scales and questionnaires. 2nd ed. New York (NY): Oxford University Press, 1996
14.
Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis 1981; 34: (12): 585–97PubMedCrossRef
15.
Stewart AL, Hays RD, Ware JE. The MOS short-form general health survey. Reliability and validity in a patient population. Med Care 1988; 26: 724–35PubMedCrossRef
16.
Moyer CA, Fendrick AM. Measuring health-related quality of life in patients with upper gastrointestinal disease. Dig Dis 1998; 16: 315–24PubMedCrossRef
17.
Raymond JM, Marquis P, Bechade D, et al. Assessment of quality of life of patients with gastroesophageal reflux: elaboration and validation of a specific questionnaire. Gastroenterol Clin Biol 1999; 23: (1): 32–9PubMed
18.
Revicki DA, Crawley JA, Zodet MW, et al. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastroesophageal reflux disease. Aliment Pharmacol Ther 1999; 13: 1621–30PubMedCrossRef
19.
Farup CE, Leidy NK, Murray M, et al. Effect of domperidone on the health-related quality of life of patients with symptoms of diabetic gastroparesis. Diabetes Care 1998; 21: 1699–706PubMedCrossRef
20.
Kuykendall DH, Rabeneck L, Campbell CJM, et al. Dyspepsia: how should we measure it? J Clin Epidemiol 1998; 51: 99–106PubMedCrossRef
21.
Revicki DA, Wood M, Maton PN, et al. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998; 104: 252–8PubMedCrossRef
22.
Wiklund I, Glise H, Jerndal P, et al. Does endoscopy have a positive impact on quality of life in dyspepsia? Gastrointest Endosc 1998; 47: 449–54PubMedCrossRef
23.
Wiklund IK, Junghard O, Grace E, et al. Quality of life in reflux and dyspepsia patients: psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg Suppl. 1998; 164 (583): 41–9
24.
Wiklund I, Bardhan KD, Muller-Lissner S, et al. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. Ital J Gastroenterol Hepatol 1998; 30: 19–27PubMed
25.
Hahn BA, Kirchdoerfer LJ, Fullerton S, et al. Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life. Aliment Pharmacol Ther 1997; 11: 553–9PubMedCrossRef
26.
Whitehead WE, Burnett CK, Cook III EW, et al. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci 1996; 41: 2248–53PubMedCrossRef
27.
O’Keefe EA, Talley NJ, Zinsmeister AR, et al. Bowel disorders impair functional status and quality of life in the elderly: a population-based study. J Gerontol 1995; 50: M184-M189
28.
Drossman DA, Li Z, Toner BB, et al. Functional bowel disorders: a multicenter comparison of health status and development of illness severity index. Dig Dis Sci 1995; 40: 986–95PubMedCrossRef
29.
Dancey CP, Backhouse S. Towards a better understanding of patients with irritable bowel syndrome. J Adv Nurs 1993; 18: 1443–50PubMedCrossRef
30.
Hahn BA, Kirchdoerfer LJ, Fullerton S, et al. Evaluation of a new quality of life questionnaire for patients with irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 547–52PubMedCrossRef
31.
Dupuy HJ. The Psychological General Well-Being (PGWB) Index. In: Wender NK, Mattson ME, Furberg CD, et al., editors. Assessment of quality of life in clinical trials of cardiovascular therapies. New York (NY): Le Jacq, 1984: 170–83
32.
Revicki DA, Sorensen S, Maton PN, et al. Health-related quality of life outcomes of omeprazole versus ranitidine in poorly responsive symptomatic gastroesophageal reflux disease. Dig Dis 1998; 16: 284–91PubMedCrossRef
33.
Glise H, Hallerback B, Johansson B. Quality of life assessments in the evaluation of gastroesophageal reflux and peptic ulcer disease before, during and after treatment. Scand J Gastroenterol 1995; 30 Suppl. 208: 133–5CrossRef
34.
Glise H, Hallerback B, Johansson B. Quality of life assessments in evaluation of laparoscopic Rosetti fundoplication. Surg Endosc 1995; 9: 183–9PubMedCrossRef
35.
Blomqvist A, Lonroth H, Dalenback J, et al. Quality of life assessment after laparoscopic and open fundoplications. Scand J Gastroenterol 1996; 31: 1052–8PubMedCrossRef
36.
Dimenas E, Carlsson G, Glise H, et al. Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol 1996; 31 Suppl. 221: 8–13CrossRef
37.
Revicki DA, Leidy NK, Howland L. Evaluating the psychometric characteristics of the Psychological General Well-Being Index with a new response scale. Qual Life Res 1996; 5: 419–24PubMedCrossRef
38.
Galmiche J-P, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997; 11: 765–73PubMedCrossRef
39.
Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Euro J Hepatol 1998; 10: 119–24CrossRef
40.
Mattsson C, Lundell L, Nystrom P, et al. Quality of life (QOL) in the long term management of gastroesophageal reflux disease treated with omeprazole (OME) or antireflux surgery (ARS) [abstract]. Qual Life Res 1998; 7: 635
41.
Ware JE Jr, Snow KK, Kosinski M, et al. SF-36 health survey: manual and interpretation guide. Boston (MA): The Health Institute, New England Medical Center, 1993
42.
Ware Jr JE, Kosinski M, Keller SD. SF-36 physical and mental health summary scales: a user’s manual. Boston (MA): The Health Institute, New England Medical Center, 1994
43.
Silvers D, Kipnes M, Broadstone V, et al. Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality of life outcomes in a multicenter controlled trial. Clin Ther 1998; 20: 438–53PubMedCrossRef
44.
Rush DR, Stelmach WJ, Young TL, et al. Clinical effectiveness and quality of life with ranitidine vs. placebo in gastroesophageal reflux disease patients: a clinical experience network (CEN) study. J Fam Pract 1995; 41: 126–36PubMed
45.
Stacey JH, Miocevich ML, Sacks GE. The effect of ranitidine (as effervescent tablets) on the quality of life of GORD patients. Br J Clin Pract 1996; 50: 190–6PubMed
46.
Young TL, Kirchdoerfer LJ, Osterhaus JT. A development and validation process for a disease-specific quality of life instrument. Drug Info J 1996; 30: 185–93CrossRef
47.
Heaney A, Collins JSA, Watson RGP, et al. A prospective randomized trial of a ‘test and treat’ policy versus endoscopy based management in young Helicobacter pylori positive patients with ulcer-like dyspepsia, referred to a hospital clinic. Gut 1999; 45: 186–90PubMedCrossRef
48.
Talley NJ, Vakil N, Ballard ED, et al. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med 1999; 341: 1106–11PubMedCrossRef
49.
Martin C, Marquis P, Bonfils S. A ‘quality of life questionnaire’ adapted to duodenal ulcer therapeutic trials. Scand J Gastroenterol 1994; Suppl. 206: 40–3
50.
Mathias SD, Castell,MD, Elkin EP, et al. Health-related quality of life of patients with acute erosive reflux esophagitis. Dig Dis Sci 1996; 41: 2123–9PubMedCrossRef
51.
McDougall MI, Johnston BT, Kee F, et al. Natural history of reflux oesophagitis: a 10-year follow up of its effects on patient symptomatology and quality of life. Gut 1996; 38: 481–6PubMedCrossRef
52.
Bityutskiy JP, Soykan I, McCallum RW. Viral gastroparesis: a subgroup of idiopathic gastroparesis — clinical characteristics and long-term outcomes. Am J Gastroenterol 1997; 92: 1501–4PubMed
53.
Soykan I, Sarosiek I, McCallum RW. The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis. Am J Gastroenterol 1997; 92: 976–80PubMed
54.
Dimenas E, Glise H, Hallerback B, et al. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol 1995; 30: 1046–52PubMedCrossRef
55.
Moayyedi P, Feltbower R, Brown J, et al. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Lancet 2000; 355: 1665–9PubMedCrossRef
56.
Meineche-Schmidt V, Talley NJ, Pap A, et al. Impact of functional dyspepsia on quality of life and health care consumption after cessation of antisecretory treatment. Scand J Gastroenterol 1999; 34: 566–74PubMedCrossRef
57.
Talley NJ, Meineche-Schmidt V, Paré P, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomised, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998; 12: 1055–65PubMedCrossRef
58.
Colwell HH, Mathias SD, Pasta DJ, et al. Development of a health-related quality-of-life questionnaire for individuals with gastroesophageal reflux disease. Dig Dis Sci 1999; 44: 1376–83PubMedCrossRef
59.
Talley NJ, Weaver AL, Zinsmeister AR. Impact of functional dyspepsia on quality of life. Dig Dis Sci 1995; 40: 584–9PubMedCrossRef
60.
Cutts TF, Abell TL, Karas JG, et al. Symptom improvement from prokinetic therapy corresponds to improved quality of life in patients with severe dyspepsia. Dig Dis Sci 1996; 41: 1369–78PubMedCrossRef
61.
Eypasch E, Williams JI, Wood-Dauphinee S, et al. Gastrointestinal Quality of Life Index: development, validation and application of a new instrument. Br J Surg 1995; 82: 216–22PubMedCrossRef
62.
Chassany O, Marquis P, Scherrer B, et al. Validation of a specific quality of life questionnaire for functional digestive disorders. Gut 1999; 44: 527–33PubMedCrossRef
63.
Marquis P, Sapede C, Bechade D, et al. Development and psychometric validation of a disease-specific quality of life questionnaire in gastro-oesophageal reflux. Qual Life Res 1995; 4: 457–8CrossRef
64.
Bamfi F, Olivieri A, Arpinelli F, et al. Measuring quality of life in dyspeptic patients: development and validation of a new specific health status questionnaire: final report from the Italian QPD project involving 4000 patients. Am J Gastroenterol 1999; 94 (3): 730–8PubMed
65.
Talley NJ, Haque M, Wyeth JW, et al. Development of a new dyspepsia impact scale: the Nepean Dyspepsia Index. Aliment Pharmacol Ther 1999; 13: 225–35PubMedCrossRef
66.
Patrick DL, Drossman DA, Frederick IO, et al. Quality of life in persons with irritable bowel syndrome. Development and validation of a new measure. Dig Dis Sci 1998; 43: 400–11PubMedCrossRef
67.
Kamolz T, Bammer T, Wykypiel Jr H, et al. Quality of life and surgical outcome after laparoscopic nissen and toupet fundoplication: one-year follow-up. Endoscopy 2000; 32: 363–8PubMedCrossRef
68.
Varga G, Király Á, Moizs M, et al. Effect of laparoscopic antireflux operation on esophageal manometry, 24 hours pH-metry and quality of life in gastroesophageal reflux disease. Acta Chir Hung 1999; 38: 213–8PubMed
69.
Heymann-Mönnikes I, Arnold R, Florin I, et al. The combination of medical treatment plus multicomponent behavioral therapy is superior to medical treatment alone in the therapy of irritable bowel syndrome. Am J Gastroenterol 2000; 95: 981–94PubMed
70.
Drossman DA, Patrick DL, Whitehead WE, et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol 2000; 95: 999–1007PubMedCrossRef
71.
Talley NJ, Verlinden M, Jones M. Validity of a new quality of life scale for functional dyspepsia: a United States multicenter trial of the Nepean Dyspepsia Index. Am J Gastroenterol 1999; 94: 2390–7PubMedCrossRef
72.
Hahn BA, Yan S, Strassels S. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom. Digest 1999; 60: 77–81CrossRef
73.
Svedlund J, Sjodin I, Dotevall G. GSRS — a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988; 33: 129–34PubMedCrossRef
74.
Revicki DA, Wood M, Wiklund I, et al. Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease. Qual Life Res 1998; 7: 75–83PubMedCrossRef
75.
Festen HPM, Schenk E, Tan G, et al. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. Am J Gastroentrol 1999; 94: 931–6CrossRef
76.
Mold JW, Reed LE, Davis AB, et al. Prevalence of gastroesophageal reflux in elderly patients in a primary care setting. Am J Gastroenterol 1991; 86: 965–70PubMed
77.
Ruth M, Mansson I, Sandberg N. The prevalence of symptoms suggestive of esophageal disorders. Scand J Gastroenterol 1991; 26; 73–81PubMedCrossRef
78.
Raiha IJ, Impivaara O, Seppala M, et al. Prevalence and characteristics of symptomatic gastroesophageal reflux disease in the elderly. J Am Geriatr Soc 1992; 40: 1209–11PubMed
79.
Johnsson F, Roth Y, Pedersen NED, et al. Cimetidine improves GERD symptoms in patients selected by a validated GERD questionnaire. Aliment Pharmacol Ther 1993; 7: 81–6PubMedCrossRef
80.
Velanovich V, Vallance SR, Gusz JR, et al. Quality of life scale for gastroesophageal reflux disease. J Am Coll Surg 1996; 183: 217–24PubMed
81.
Locke GR, Talley NJ, Pett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448–56PubMedCrossRef
82.
Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997; 92: 1997–2000PubMed
83.
Carlsson R, Dent J, Bolling-Sternevald F, et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998; 33: 1023–9PubMedCrossRef
84.
Rothman M, Farup C, Stewart W, et al. Symptoms associated with gastroesophageal reflux disease: development of a questionnaire for use in clinical trials. Dig Dis Sci. In press
85.
Velanovich V, Karmy-Jones R. Measuring gastroesophageal reflux disease relationship between the health-related quality of life score and physiologic parameters. Am Surg 1998; 64: 649–53PubMed
86.
Veldhuyzen van Zanten SJO, Tytgat KMAJ, Pollak PT, et al. Can severity of symptoms be used as an outcome measure in trials of non-ulcer dyspepsia and Helicobacter pylori associated gastritis? J Clin Epidemiol 1993; 46: 273–9CrossRef
87.
Garratt AM, Ruta DA, Russell I, et al. Developing a condition specific measure of health for patients with dyspepsia and ulcer-related symptoms. J Clin Epidemiol 1996; 49: 565–71PubMedCrossRef
88.
Buckley MJ, Scanlon C, McGurgan P, et al. A validated dyspepsia symptom score. Ital J Gastroenterol Hepatol 1997; 29: 495–500PubMed
89.
Junghard O, Wiklund I, Lauritsen K, et al. Validation of seven graded diary cards for severity of dyspeptic symptoms in patients with non-ulcer dyspepsia. Eur J Surg 1998; Suppl. 583: 106–11
90.
Leidy NK, Farup C, Rentz AM, et al. Patient-based assessment in dyspepsia: development and evaluation of the dyspepsia symptom severity index (DSSI). Dig Dis Sci 2000; 45: 1172–9PubMedCrossRef
91.
Jones KL, Wishart JM, Berry MK, et al. Effects of fedotozine on gastric emptying and upper gastrointestinal symptoms in diabetic gastroparesis. Aliment Pharmacol Ther 2000; 14: 937–43PubMedCrossRef
92.
Mansi C, Borro P, Giacomini M, et al. Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis. Aliment Pharmacol Ther 2000; 14: 561–9PubMedCrossRef
93.
Abell TL, Cutts TF, Cooper T. Effect of cisapride therapy for severe dyspepsia on gastrointestinal symptoms and quality of life. Scand J Gastroenterol 1993; 28 Suppl. 195: 60–4CrossRef
94.
El-Omar EM, Banerjee S, Wirz A, et al. The Glasgow dyspepsia severity score — a tool for the global measurement of dyspepsia. Euro J Gastroenterol Hepatol 1996; 8: 967–71CrossRef
95.
Kay L, Jorgensen T, Jensen KH. Epidemiology of abdominal symptoms in random population: prevalence, incidence, and natural history. Euro J Epidemiol 1994; 10: 559–66CrossRef
96.
Talley NJ, Philips SP, Melton III LJ, et al. A patient questionnaire to identify bowel disease. Ann Intern Med 1989; 111: 671–4PubMed
97.
O’Keefe EA, Talley NJ, Tangalos EG, et al. A bowel symptom questionnaire for the elderly. J Gerontol 1992; 47: M116-M121CrossRef
98.
Janatuinen E, Pikkarainen P, Laakso M, et al. Gastrointestinal symptoms in middle-aged diabetic patients. Scand J Gastroenterol 1993; 28: 427–32PubMedCrossRef
99.
Shaw M, Talley NJ, Adlis S, et al. Development of a digestive health status instrument: tests of scaling assumptions, structure and reliability in a primary care population. Aliment Pharmacol Ther 1998; 12: 1067–78PubMedCrossRef
100.
Horowitz M, Harding PE, Chatterton BE, et al. Acute and chronic effects of domperidone on gastric emptying in diabetic autonomic neuropathy. Dig Dis Sci 1985; 30: 1–9PubMedCrossRef
101.
Blum AL, Talley NJ, O’Moráin C, et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998; 339: 1875–81PubMedCrossRef
102.
Miwa H, Hirai S, Nagahara A, et al. Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2000; 14: 317–24PubMedCrossRef
103.
Velanovich V. Comparison of symptomatic and quality of life outcomes of laparoscopic versus open antireflux surgery. Surgery 1999; 126: 782–9PubMedCrossRef
104.
Talley NJ, Janssens J, Lauritsen K, et al. Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months follow up. BMJ 1999; 318: 833–7PubMedCrossRef
105.
Cook KF, Rabeneck L, Campbell CJM, et al. Evaluation of a multidimensional measure of dyspepsia-related health for use in a randomized clinical trial. J Clin Epidemiol 1999; 52: 381–92PubMedCrossRef
106.
Quartero AO, Post MWM, Numans ME, et al. What makes the dyspeptic patient feel ill? A cross sectional survey of functional health status, Helicobacter pylori infection, and psychological distress in dyspeptic patients in general practice. Gut 1999; 45: 15–9PubMedCrossRef
107.
Farup PG, Hovdenak N, Wetterhus S, et al. The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation. Scand J Gastroenterol 1998; 33: 128–31PubMedCrossRef
108.
Noor N, Small PK, Loudon MA, et al. Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome. Scand J Gastroenterol 1998; 33: 605–11PubMedCrossRef
109.
Drossman DA, Richter JE, Talley NJ, et al. The functional gastrointestinal disorders: diagnosis, pathophysiology, and treatment: a multinational consensus. McLean (VA): Degnon Associates, 1994
110.
Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997; 11: 395–402PubMedCrossRef
111.
Guthrie EA, Creed FH, Whorwell PJ, et al. Outpatients with irritable bowel syndrome: a comparison of first time and chronic attenders. Gut 1992; 33: 361–3PubMedCrossRef
112.
Hunt S. Cross-cultural issues in the use of quality of life measures in randomized controlled trials. In: Staquet MJ, Hays RD, Fayers PM, editors. Quality of life assessment in clinical trials: methods and practice. Oxford: Oxford University Press, 1998: 51–68
113.
Cella DF, Lloyd SR, Wright BD. Cross-cultural instrument equating: current research and future directions. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia (PA): Lippincott-Raven, 1996: 707–15
114.
Osoba D. Guidelines for measuring health-related quality of life in clinical trials. In: Staquet MJ, Hays RD, Fayers PM, editors. Quality of life assessment in clinical trials. Oxford: Oxford University Press, 1998: 19–35
115.
Osoba D. Measuring the effect of cancer on quality of life. In: Osoba D, editor. Effect of cancer on quality of life. Boca Raton (FL): CRC Press, 1991: 25–40
116.
Osoba D, Aaronson NK, Till JE. A practical guide for selecting quality-of-life measures in clinical trials and practice. In: Osoba D, editor. Effect of cancer on quality of life. Boca Raton (FL): CRC Press, 1991: 89–111
117.
Irvine EJ, Feagan BG, Wong CJ. Does self-administration of a quality of life index for inflammatory bowel disease change the results? J Clin Epidemiol 1996; 49: 1177–85PubMedCrossRef
118.
Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993; 118: 622–9PubMed
Metadata
Title
Symptom and Health-Related Quality-of-Life Measures for Use in Selected Gastrointestinal Disease Studies
A Review and Synthesis of the Literature
Authors
Anne M. Rentz
Carmelina Battista
Elyse Trudeau
Robert Jones
Patricia Robinson
Sheldon Sloan
Sonika Mathur
Lori Frank
Dennis A. Revicki
Publication date
01-04-2001
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 4/2001
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200119040-00003

Other articles of this Issue 4/2001

PharmacoEconomics 4/2001 Go to the issue

Original Research Article

Cost-Effectiveness Analysis of n-3 Polyunsaturated Fatty Acids (PUFA) after Myocardial Infarction

Adis Pharmacoeconomic Drug Evaluation

Efavirenz

Review Article

Pharmacoeconomics of Hypertension Management

Leading Article

On Individual Preferences and Aggregation in Economic Evaluation in Healthcare

Original Research Article

Cost-Benefit Analysis of a Haemophilus Influenzae Type B Meningitis Prevention Programme in The Philippines

Original Research Article

Cost Effectiveness of Continuous Terbinafine Compared with Intermittent Itraconazole in the Treatment of Dermatophyte Toenail Onychomycosis